Search - tctmd.com

Displaying 1 - 20 of 50

Sort: Relevancy | Date

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

December 10, 2019

Year in Review: ISCHEMIA Tops Coronary News in 2019 but Other Trials Shine, Too

News Features

Year in Review: ISCHEMIA Tops Coronary News in 2019 but Other Trials Shine, Too

Michael O'Riordan

December 09, 2019

Aspirin Discontinuation Safe, Effective Strategy in ACS Subset: TWILIGHT

News Conference News AHA 2019

Aspirin Discontinuation Safe, Effective Strategy in ACS Subset: TWILIGHT

Yael L. Maxwell

November 17, 2019

Women Bleed More Than Men After PCI, GLOBAL LEADERS Affirms

News Daily News

Women Bleed More Than Men After PCI, GLOBAL LEADERS Affirms

November 07, 2019

TCTMD’s Top 10 Most Popular Stories for October 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2019

October 31, 2019

Troponin Increases After Elective PCI Tied to Complexity, Extent of CAD

News Daily News

Troponin Increases After Elective PCI Tied to Complexity, Extent of CAD

October 29, 2019

DAPT Cuts Saphenous Vein Graft Failure After CABG: Meta-analysis

News Daily News

DAPT Cuts Saphenous Vein Graft Failure After CABG: Meta-analysis

Michael O'Riordan

October 17, 2019

Ticagrelor Monotherapy After Multivessel PCI? Latest Slice From GLOBAL LEADERS Says . . . Maybe

News Daily News

Ticagrelor Monotherapy After Multivessel PCI? Latest Slice From GLOBAL LEADERS Says . . . Maybe

Yael L. Maxwell

October 16, 2019

FDA Gives Rivaroxaban Another VTE-Related Indication

News Daily News

FDA Gives Rivaroxaban Another VTE-Related Indication

October 14, 2019

Sex-Specific Troponin Cutoffs Find Many More Women With Myocardial Injury

News Daily News

Sex-Specific Troponin Cutoffs Find Many More Women With Myocardial Injury

October 14, 2019

IVUS-XPL at 5 Years Shows Durability of Imaging Guidance in PCI

News Conference News TCT 2019

IVUS-XPL at 5 Years Shows Durability of Imaging Guidance in PCI

October 08, 2019

TICAKOREA: Ticagrelor Ups Bleeding Over Clopidogrel in Korean ACS Patients

News Conference News TCT 2019

TICAKOREA: Ticagrelor Ups Bleeding Over Clopidogrel in Korean ACS Patients

October 03, 2019

News Conference News TCT 2019

GLOBAL LEADERS Post Hoc: Okay to Drop Aspirin After 1 Month in ACS Patients?

September 30, 2019

Off Script: A (Not So) Brief History of Aspirin’s Rise and Fall

News Opinion Off Script TCT 2019

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

September 29, 2019

The Role of Antiplatelet Agents in Patients With Diabetes and Coronary Disease

Presentation TCT 2019

The Role of Antiplatelet Agents in Patients With Diabetes and Coronary Disease

Presenter: Marc Bonaca

September 26, 2019

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

News Conference News TCT 2019

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

September 26, 2019

News TCT 2019

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

September 26, 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

News Conference News TCT 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

September 26, 2019

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

News Conference News TCT 2019

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

September 26, 2019

https://www.tctmd.com/news/ideal-lm-probes-short-dapt-and-bioabsorbable-polymer-stent-left-main-disease

News Conference News TCT 2019

IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease

Michael O'Riordan

September 26, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.